Featured Research

from universities, journals, and other organizations

Voice Box Can Be Preserved, Even With The Largest Cancers, Study Suggests

Date:
June 29, 2009
Source:
University of Michigan Health System
Summary:
Some patients with large tumors on their larynx can preserve their speech by opting for chemotherapy and radiation over surgery to remove the voice box. A new study found that a single round of chemotherapy could identify those patients most likely to benefit from this approach.

Some patients with large tumors on their larynx can preserve their speech by opting for chemotherapy and radiation over surgery to remove the voice box.

A new study from the University of Michigan Comprehensive Cancer Center found that a single round of chemotherapy could identify those patients most likely to benefit from this approach.

“Organ preservation studies have excluded these patients because their tumors are so large. We found that if a patient’s tumor does not respond to chemotherapy, the patient can be instantly referred for a laryngectomy, which is the standard of care. But if the tumor responded to the drugs, perhaps some of those people could survive the cancer with their voice box intact,” says lead study author Francis P. Worden, M.D., associate professor of internal medicine at the U-M Medical School.

Researchers reviewed data from two U-M studies of advanced laryngeal cancer patients, looking specifically at patients who had the largest tumors, called T4. In addition to being large, T4 tumors have often invaded the nearby cartilage, making them particularly difficult to treat.

Study participants were given one round of induction chemotherapy, an initial dose designed to see if the cancer responds. If the tumor shrank by more than 50 percent after that first round, study participants were given three more rounds of chemotherapy, combined with daily radiation therapy.

Those whose tumors did not respond to the induction chemotherapy were referred for surgery.

Thirty-six people with T4 disease were enrolled in the two studies. Eighty-one percent responded to the induction chemotherapy and many saw their tumors shrink completely. After three years, 78 percent of the T4 study participants were still alive, and 58 percent still had an intact larynx.

While chemotherapy and radiation come with unpleasant and serious side effects, avoiding surgery allows patients to retain their voice. The study found that people who preserved their larynx reported better quality of life and less depression than those who had surgery. Few people required a feeding tube or tracheostomy.

“If the patient failed chemotherapy up front, he or she could go straight to surgery and avoid the side effects of chemo-radiation,” Worden says. “Meanwhile, a large group of patients get to preserve their voice box by avoiding laryngectomy.”

“We saw no survival difference between the smallest and the largest tumors, which suggests that organ preservation is a viable alternative to surgery for some of the largest laryngeal cancers,” he adds.

Laryngeal cancer statistics: 12,290 Americans will be diagnosed with laryngeal cancer this year and 3,660 will die from the disease, according to the National Cancer Institute

Additional authors: Jeffrey Moyer, M.D.; Julia S. Lee; Jeremy M.G. Taylor, Ph.D.; Susan G. Urba, M.D.; Avraham Eisbruch, M.D.; Theodoros N. Teknos, M.D.; Douglas B. Chepeha, M.D.; Mark E. Prince, M.D.; Norman Hogikyan, M.D.; Amy Anne D. Lassig, M.D.; Kevin Emerick, M.D.; Suresh Mukherji, M.D.; Lubomir Hadjiski, Ph.D.; Christina I. Tsien, M.D.; Tamara H. Miller; Nancy E. Wallace; Heidi L. Mason, N.P.; Carol R. Bradford, M.D.; and Gregory T. Wolf, M.D.

Funding: National Institutes of Health, U-M Head and Neck Cancer SPORE grant, U-M Comprehensive Cancer Center support grant

Reference: Laryngoscope, DOI: 10.1002/lary.20294


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Voice Box Can Be Preserved, Even With The Largest Cancers, Study Suggests." ScienceDaily. ScienceDaily, 29 June 2009. <www.sciencedaily.com/releases/2009/06/090625133209.htm>.
University of Michigan Health System. (2009, June 29). Voice Box Can Be Preserved, Even With The Largest Cancers, Study Suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/06/090625133209.htm
University of Michigan Health System. "Voice Box Can Be Preserved, Even With The Largest Cancers, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/06/090625133209.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins